StockData
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Sagimet Biosciences Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.86+0.84 (+10.47%)

Close on Oct 19, 2026

Market cap
$470.59M
P/E (TTM)
–
Dividend yield
–

Sagimet Biosciences Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Sagimet Biosciences does not break out revenue by segment, region or product in the tagged data of its filings for this period type.